Analyst initiations: Pharmaceutical stocks, RIGL and CELL
Posted Oct 24th 2007 11:30AM by Eric Buscemi
Filed under: Analyst reports, Merck and Co (MRK), Lilly (Eli) (LLY), Analyst initiations
.gif)
MOST NOTEWORTHY: Global pharmaceutical stocks, Rigel Pharmaceuticals and Brightpoint were today's noteworthy initiations:
- Bernstein initiated global pharmaceutical stocks with a Cautious view. The firm initiated Merck & Co Inc (NYSE: MRK), Schering Plough Corporation (NYSE: SGP) and Wyeth (NYSE: WYE) with Outperform ratings, as well as Bristol-Myers Squibb Company (NYSE: BMY) and Eli Lilly & Company (NYSE: LLY) with Market Perform ratings.
- CIBC resumed coverage of Rigel Pharmaceuticals Inc (NASDAQ: RIGL) with a Sector Outperformer rating and $16 target. The firm expects near-term upside to be driven by positive phase 2 results of R788 in rheumatoid arthritis, expected in December, and thinks the company's strong scientific platform will support long-term appreciation.
- Bear Stearns started Brightpoint Incorporated (NASDAQ: CELL) with an Outperform rating and $20 target, as they are positive on Brightpoint's merger with Dangaard given the significant synergies and diversification it provides.
OTHER INITIATIONS:
Tags: BMY, Brightpoint, Bristol Myers, BristolMyers, CELL, Eli Lilly, EliLilly, Genitope, GTOP, initiations, LLY, merck, MRK, Pharmaceutical, Rigel Pharmaceuticals, RigelPharmaceuticals, RIGL, Schering Plough, ScheringPlough, SGP, WYE, Wyeth
Related Posts
- ETF Investing: We Get Sick In Recessions! XPH and IHI Healthcare Stocks (12 days ago - 1 Comments)
- Analyst calls: SNV, BASFY, AKZOY, FUL, GA, WLT, AHD, OZM, HOG, MRK (18 days ago - 0 Comments)
- Wyeth's (WYE) PREMARIN gets FDA approval (19 days ago - 1 Comments)
- Pfizer cancels obesity drug, the latest to do so (26 days ago - 1 Comments)
- Before the bell: Set for a lower start; SNE, GS, AMZN, AMGN, DOW, XRX ... (40 days ago - 1 Comments)
Where have all the consumers gone?
Yahoo! soars on report that former AOL CEO wants to buy
What ever happened to GE?
